Genvor is a research and development (“R&D”) company, advancing the next generation of sustainable plant health solutions, which are designed to fight debilitating and deadly plant diseases, such as bacteria and fungi, in a broad spectrum of crop types through its proprietary library of patented anti-microbial peptides, or AMPs. These AMPs can be applied to plants in the form of non-chemical seed traits (“Transgenic” seed traits) – which imbue seeds with the desired traits, allowing plants to naturally produce Genvor’s AMPs – as well as a topical spray (“Bio-pesticide”) application. The AMPs are intended to help farmers worldwide achieve healthier and more productive crops, boosting yields and overcoming potentially catastrophic losses.
Company profile
Ticker
GNVR
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Allure Worldwide, Inc.
SEC CIK
IRS number
832054746
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
20 Mar 24
10-Q
2024 Q1
Quarterly report
14 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Jan 24
8-K/A
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
18 Jan 24
10-K
2023 FY
Annual report
16 Jan 24
10-K/A
2022 FY
Annual report (amended)
16 Jan 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 24 | Chad Lee Sr. Pawlak | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 100,000 |
15 Mar 24 | Judith Selene Miller | Common Stock | Grant | Acquire A | Yes | No | 0 | 25,000 | 0.00 | 1,071,170 |
16 Feb 24 | Judith Selene Miller | Common Stock | Grant | Acquire A | Yes | No | 0 | 25,000 | 0.00 | 1,046,170 |
Press releases
Genvor to Unveil Latest Research on Patented Peptides for Aflatoxin Resistance in Corn at BioAgTech World Congress
22 Apr 24
Genvor to Participate in BioAgTech World Congress in Raleigh, North Carolina
2 Apr 24
Genvor to Participate in World Agri-Tech Innovation Summit in San Francisco
27 Feb 24
Genvor Provides Fiscal First Quarter 2024 Corporate Update
15 Feb 24